Etripamil is a Small Molecule owned by Milestone Pharmaceuticals, and is involved in 13 clinical trials, of which 6 were completed, 4 are ongoing, and 3 are planned.

Etripamil (MSP-2017) acts as a calcium channel blocker. The drug candidate prevents calcium from entering cells of the heart and blood vessel walls, resulting in lower blood pressure. The drug candidate relaxes, widen blood vessels by affecting the muscle cells in the arterial walls.

The revenue for Etripamil is expected to reach a total of $2.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Etripamil NPV Report.

Etripamil is originated and owned by Milestone Pharmaceuticals.

Etripamil Overview

Etripamil (MSP-2017) is under development for the treatment of transient cardiovascular conditions such as paroxysmal supraventricular tachycardia (PSVT), stable angina and atrial fibrillation. The drug candidate is a short-acting therapeutic administered by intranasal route as a spray. It is a new chemical entity and acts by targeting calcium channel.

Milestone Pharmaceuticals Overview

Milestone Pharmaceuticals is a Pharmaceutical company. It develops novel small molecule therapeutics. The company undertakes the development of small molecule therapeutics based on clinically validated mechanisms, for the treatment of cardiovascular diseases. The company’s lead product etripamil, is a potent short-acting calcium channel antagonist for the systemic treatment of cardiovascular conditions such as angina, paroxysmal supraventricular tachycardia and atrial arrhythmias. It offers products through nasal sprays for the provision of rapid systemic drug delivery that can be used by electrocardiogram (ECG)-diagnosed patient. It operates in the US and Canada. Milestone Pharmaceuticals is headquartered in Saint-Laurent, Quebec, Canada.

The company reported revenues of (US Dollars) US$15 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$43.1 million in FY2021, compared to an operating loss of US$50.7 million in FY2020. The net loss of the company was US$42.9 million in FY2021, compared to a net loss of US$50 million in FY2020.

Quick View – Etripamil

Report Segments
  • Innovator
Drug Name
  • Etripamil
Administration Pathway
  • Nasal
Therapeutic Areas
  • Cardiovascular
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.